U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. La Vita Compounding Pharmacy, LLC - 575286 - 09/03/2020
  1. Warning Letters

CLOSEOUT LETTER

La Vita Compounding Pharmacy, LLC MARCS-CMS 575286 —

Delivery Method:
Electronic Mail
Recipient:
Recipient Name
Christine A. Givant
Recipient Title
Pharmacist in Charge
La Vita Compounding Pharmacy, LLC

3978 Sorrento Valley Boulevard
Suite 300
San Diego, CA 92121-1436
United States

Issuing Office:
Division of Pharmaceutical Quality Operations IV

United States

Dear Ms. Givant:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (CMS No. 575286) dated February 28, 2019. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV

Back to Top